期刊
FEBS LETTERS
卷 594, 期 22, 页码 3602-3618出版社
WILEY
DOI: 10.1002/1873-3468.13917
关键词
angiogenesis; Gb5; GD2; Globo H; glycosphingolipids; immunotherapeutics
资金
- Ministry of Science and Technology of Taiwan [MOST 109-2321-B-182A-005]
- Ministry of Health and Welfare of Taiwan [MOHW109-TDU-B-212-134010]
- Chang Gung Memorial Hospital at Linkou of Taiwan [OMRPG3C0047, CMRPG 3F0973, OMRPG3C0018, CMRPG3G1531CMRPG3G1533]
Aberrant expression of glycosphingolipids (GSLs) is a unique feature of cancer and stromal cells in tumor microenvironments. Although the impact of GSLs on tumor progression remains largely unclear, anticancer immunotherapies directed against GSLs are attracting growing attention. Here, we focus on GD2, a disialoganglioside expressed in tumors of neuroectodermal origin, and Globo H ceramide (GHCer), the most prevalent cancer-associated GSL overexpressed in a variety of epithelial cancers. We first summarize recent advances on our understanding of GD2 and GHCer biology and then discuss the clinical development of the first immunotherapeutic agent targeting a glycolipid, the GD2-specific antibody dinutuximab, its approved indications, and new strategies to improve its efficacy for neuroblastoma. Next, we review ongoing clinical trials on Globo H-targeted immunotherapeutics. We end with highlighting how these studies provide sound scientific rationales for targeting GSLs in cancer and may facilitate a rational design of new GSL-targeted anticancer therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据